CMS also elevated 5-HT2A, 5-HT2C, and 5-HT7 receptor expression, mitigated by GNR-E (150–450 mg/kg) and imipramine, consistent with studies linking these receptors to depression-like behaviors and their reversal by antagonists. Here, HTR2A is linked to depressive symptom measurement.